Picture loading failed.

Pre-Made Domagrozumab biosimilar, Whole mAb, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-151-1mg 1mg 3090
GMP-Bios-ab-151-10mg 10mg Inquiry
GMP-Bios-ab-151-100mg 100mg Inquiry
GMP-Bios-ab-151-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Domagrozumab biosimilar, Whole mAb, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody
INN Name Domagrozumab
TargetGDF-8
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI Structure5f3h:EF:GH:AB:CD
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesKennedy Krieger Institute;Pfizer
Conditions Approvedna
Conditions Activena
Conditions Discontinuedna
Development Techna